Verapamil's Effect on Liver Cancer in Rats
Author Information
Author(s): H. Uehara, A. Nakaizumi, M. Baba, H. Jishi, M. Tatsuta
Primary Institution: Department of Gastrointestinal Oncology, The Center for Adult Diseases, Osaka
Hypothesis
Does verapamil inhibit hepatocarcinogenesis induced by N-nitrosomorpholine in rats?
Conclusion
Verapamil significantly reduces the number and size of liver lesions and hepatocellular carcinomas in rats treated with a carcinogen.
Supporting Evidence
- Rats treated with verapamil had significantly fewer liver lesions compared to controls.
- The volume of hepatocellular carcinomas was significantly lower in the verapamil group.
- Labelling indices of pre-neoplastic lesions were significantly reduced with verapamil treatment.
Takeaway
Verapamil helps prevent liver cancer in rats by stopping the growth of harmful cells.
Methodology
Male Sprague-Dawley rats were given a carcinogen and treated with verapamil or a control solution, with various measurements taken at the end of the study.
Limitations
The study was conducted on rats, which may not fully represent human responses.
Participant Demographics
Young male Sprague-Dawley rats, initially weighing 80-100 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website